Natco Pharma Q3 FY24 Results Live : profit rise by 241.41% YOY
Natco Pharma declared their Q3 FY24 results on 14 Feb, 2024. The topline increased by 54.03% & the profit increased by 241.41% YoY. As compared to the previous quarter the revenue declined by 26.45% and the profit decreased by 42.36%.
The Selling, general & administrative expenses declined by 0.41% q-o-q & increased by 15.44% Y-o-Y. The operating income was down by 45.97% q-o-q & increased by 247.67% Y-o-Y. The EPS is ₹11.88 for Q3 FY24 which increased by 248.39% Y-o-Y.
Natco Pharma has delivered 2.97% return in the last 1 week, 6.41% return in last 6 months and 9.05% YTD return. Currently the Natco Pharma has a market cap of ₹15847.64 Cr and 52wk high/low of ₹928 & ₹520.25 respectively. As of 16 Feb, 2024 out of 11 analysts covering the company, 1 analyst has given Strong Sell rating, 2 analysts have given Sell rating, 2 analysts have given Hold rating, 4 analysts have given Buy rating &2 analysts have given Strong Buy rating.
The consensus recommendation as on 16 Feb, 2024 was to Hold. The company has also declared interim dividend of ₹1.25. The record date for the dividend is 26 Feb, 2024 & the ex-dividend date will be 26 Feb, 2024:FAQsQuestion : What is the Q3 FY24 profit/Loss as per company?Ans : ₹212.7CrQuestion : What is Q3 FY24 revenue?Ans : ₹758.6Cr Stay updated on quarterly results with our results calendarMilestone Alert!
Livemint tops charts as the fastest growing news website in the world
